Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fosaprepitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 18/20 | 0.73 |
| ▸ | TACR3 | P29371 | 2/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | FPR1 | P21462 | 1/20 | 0.73 |
| ▸ | GPR183 | P32249 | 1/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.73 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.73 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.73 |
| ▸ | TACR2 | P21452 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosaprepitant SCHEMBL12903477 | 1.00 | TACR1 (0.73) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL21009635 | 1.00 | TACR1 (0.73) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL19749078 | 1.00 | TACR1 (0.73) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL19749951 | 1.00 | TACR1 (0.73) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL12903486 | 0.96 | TACR1 (0.68) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL12534145 | 0.95 | TACR1 (0.72) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL19908494 | 0.94 | TACR1 (0.64) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL12534143 | 0.93 | TACR1 (0.74) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL12748225 | 0.92 | TACR1 (0.72) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL19908491 | 0.92 | TACR1 (0.61) | TACR1TACR3NR3C1CYP3A4FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3224 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-20260102417-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | KEYZELL HOLDING S L (ES) | 2026-04-16 | — | — | US | claimed |
| EP-4683713-A1 | DEUTERATED P2X3 MODULATORS | GlaxoSmithKline Intellectual Property (No.3) Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| US-20250387420-A1 | Prevention of Nausea and Vomiting from Antibody-Drug Conjugates and other Long-Acting Emetogenics | HELSINN HEALTHCARE SA (CH) | 2025-12-25 | — | — | US | claimed |
| EP-4255400-B1 | NEUROKININ INHIBITORS SUCH AS APREPITANT FOR TREATING NON SMALL CELL LUNG CARCINOMA WITHOUT MUTATIONS | PLUS VITECH S L (ES) | 2025-12-24 | — | — | EP | claimed |
| US-20250275979-A1 | TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2025-09-04 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| US-12403262-B2 | Tamper evident assembly with RFID for syringes | FRESENIUS KABI USA, LLC (US) | 2025-09-02 | — | — | US | claimed |
| EP-4604948-A2 | USE OF ANTAGONISTS OF NEUROKININ-1 RECEPTOR AND NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HERPESVIRIDAE | The Regents of the University of Colorado, a body corporate (US) | 2025-08-27 | — | — | EP | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| CN-102850399-A | Refining method of fosaprepitant dimeglumine | JIANGSU AOSAIKANG PHARM CO LTD | 2013-01-02 | — | — | CN | claimed |
| WO-2012146692-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF HIGHLY PURE APREPITANT OR FOSAPREPITANT | SANDOZ AG (CH) | 2012-11-01 | — | — | WO | claimed |
| WO-2012116277-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | claimed |
| EP-2303901-A2 | FOSAPREPITANT DIMEGLUMINE INTERMEDIATE, NEUTRAL FOSAPREPITANT, AND AMORPHOUS FOSAPREPITANT DIMEGLUMINE AND PROCESSES FOR THEIR PREPARATIONS | Glenmark Generics Limited (IN) | 2011-04-06 | — | — | EP | claimed |
| US-20110009629-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | SANDOZ AG (CH) | 2011-01-13 | — | — | US | claimed |
| EP-2260029-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | Sandoz AG (CH) | 2010-12-15 | — | — | EP | claimed |
| WO-2010018595-A2 | FOSAPREPITANT DIMEGLUMINE INTERMEDIATE, NEUTRAL FOSAPREPITANT, AND AMORPHOUS FOSAPREPITANT DIMEGLUMINE AND PROCESSES FOR THEIR PREPARATIONS | GLENMARK GENERICS LIMITED (IN) | 2010-02-18 | — | — | WO | claimed |
| WO-2009106486-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | SANDOZ AG (CH) | 2009-09-03 | — | — | WO | claimed |
| EP-2086641-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-08-12 | — | — | EP | claimed |
| WO-2008049842-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-02 | — | — | WO | claimed |